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Abstract
Background: CCAAT/enhancer binding protein β (C/EBPβ) is a transcription factor that regulates the expression of
important pro-inflammatory genes in microglia. Mice deficient for C/EBPβ show protection against excitotoxic and
ischemic CNS damage, but the involvement in this neuroprotective effect of the various C/EBPβ-expressing cell
types is not solved. Since C/EBPβ-deficient microglia show attenuated neurotoxicity in culture, we hypothesized
that specific C/EBPβ deficiency in microglia could be neuroprotective in vivo. In this study, we have tested this
hypothesis by generating mice with myeloid C/EBPβ deficiency.
Methods: Mice with myeloid C/EBPβ deficiency were generated by crossing LysMCre and C/EBPβfl/fl mice. Primary
microglial cultures from C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice were treated with lipopolysaccharide ± interferon γ
(IFNγ) for 6 h, and gene expression was analyzed by RNA sequencing. Gene expression and C/EBPβ deletion were
analyzed in vivo in microglia isolated from the brains of C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice treated systemically
with lipolysaccharide or vehicle. Mice of LysMCre-C/EBPβfl/fl or control genotypes were subjected to experimental
autoimmune encephalitis and analyzed for clinical signs for 52 days. One- or two-way ANOVA or Kruskal–Wallis with
their appropriate post hoc tests were used.
Results: LysMCre-C/EBPβfl/fl mice showed an efficiency of C/EBPβ deletion in microglia of 100 and 90% in vitro and in
vivo, respectively. These mice were devoid of female infertility, perinatal mortality and reduced lifespan that are
associated to full C/EBPβ deficiency. Transcriptomic analysis of C/EBPβ-deficient primary microglia revealed C/
EBPβ-dependent expression of 1068 genes, significantly enriched in inflammatory and innate immune responses GO
terms. In vivo, microglial expression of the pro-inflammatory genes Cybb, Ptges, Il23a, Tnf and Csf3 induced by
systemic lipopolysaccharide injection was also blunted by C/EBPβ deletion. CNS expression of C/EBPβ was upregulated
in experimental autoimmune encephalitis and in multiple sclerosis samples. Finally, LysMCre-C/EBPβfl/fl mice showed
robust attenuation of clinical signs in experimental autoimmune encephalitis.
Conclusion: This study provides new data that support a central role for C/EBPβ in the biology of activated microglia,
and it offers proof of concept for the therapeutic potential of microglial C/EBPβ inhibition in multiple sclerosis.
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Background
Neuroinflammation is a cellular and molecular response
of the CNS to a variety of cues, including pathogens,
abnormal protein deposits, toxic metabolites, trauma,
autoimmunity or massive cell damage, which has an
inflammatory character. Microglia, the innate immune
cells of the brain, are the main cell type involved in this
response, with astrocytes also playing a prominent role.
Chronic and/or exacerbated neuroinflammation is as-
sociated with the production of potentially cytotoxic
molecules, such as oxygen and nitrogen free radicals,
pro-inflammatory cytokines or proteases [1], and this
is thought to contribute to neurodegeneration in a grow-
ing list of neurological and psychiatric disorders [2].
In neuroinflammation, microglia undergoes massive
changes in gene expression that are regulated by a re-
duced number of transcription factors. There is strong
evidence showing that pro-inflammatory gene expression
by activated microglia is regulated by the transcription fac-
tors NF-κB, AP-1, CREB, STATs, C/EBPβ and C/EBPδ,
whereas PPARγ and Nrf2 are two of the most important
transcription factors regulating anti-inflammatory programs
in microglia [3]. Because of their bottleneck position, tran-
scription factors are potential targets to pharmacologically
modulate whole cellular programs such as the neuroinflam-
matory one in activated microglia.
The present study is focused on the role of C/EBPβ, a
transcription factor of the b-zip class, in microglial activa-
tion. The C/EBPβ gene codes for a single mRNA which
can be translated into three protein isoforms, named Full,
LAP and LIP, by use of alternative in-frame translation ini-
tiation codons [4]. C/EBPβ levels increase in activated
microglia [5] where it regulates the expression of key pro-
inflammatory genes [3, 6–8]. In vitro and in vivo data
suggest a neuroprotective potential for C/EBPβ inhibition
in microglia. Thus, neurotoxicity elicited by activated
microglia in neuronal–microglial co-cultures is abolished
by the absence of C/EBPβ in microglia [3]. Also, C/EBPβ-
deficient mice show reduced neuronal death and neuro-
logical deficits caused by ischemic [9] or excitotoxic [7]
damage in vivo. Even though these in vivo findings are
promising, ubiquitous C/EBPβ inhibition is probably un-
desirable as a therapeutic strategy because C/EBPβ plays
important roles in other cell types, such as adipocytes,
hepatocytes or neurons [4], that could be compromised.
Our hypothesis is that microglia-targeted C/EBPβ inhib-
ition could be a safe and effective approach to attenuate
neuroinflammation-driven neurodegeneration. In order to
test this hypothesis, we generated transgenic mice with
myeloid-specific C/EBPβ deficiency using a Cre-LoxP
system and transcriptomically profiled C/EBPβ-deficient
microglia. To explore the effects of C/EBPβ myeloid defi-
ciency in a pathological context, we analyzed the clinical
response of these animals to experimental autoimmune
encephalomyelitis (EAE), an animal model of multiple
sclerosis. The data here presented show that microglial
C/EBPβ absence results in remarkable effects on pro-
inflammatory gene expression programs and in the
amelioration of EAE symptomatic phenotype.
Methods
Human samples
Postmortem human temporal cortex samples were sup-
plied by the Neurological Tissue Bank of the Biobanc-
Hospital Clínic-IDIBAPS (Barcelona, Spain): healthy
controls (n = 4; 2 ♀, 2 ♂; age, 66–81 years; postmortem
delay, 3.5–23.5 h) and patients with a diagnosis of pri-
mary progressive MS (n = 5; 2 ♀, 3 ♂; age, 46–68 years;
postmortem delay, 3–8 h). Protein was extracted from
frozen tissue blocks [10], and it was processed for
Western blot analysis as described below.
Animals
Mice with myeloid C/EBPβ deficiency were generated by
crossing transgenic mice expressing Cre-recombinase
under the lysozyme M (LysM) promoter (B6.129P2-
Lyz2tm1(cre)Ifo/J 004781, Jackson Laboratories) with mice
carrying a C/EBPβ gene flanked by LoxP sites [11] kindly
donated by Prof Esta Sterneck (National Cancer Insti-
tute, Frederick, MD). These mice are referred to as
LysMCre-C/EBPβfl/fl in the manuscript. LysMCre, C/
EBPβfl/fl and LysMCre-C/EBPβfl/fl colonies, all on a C57BL/
6 background, were intercrossed every three generations to
diminish inbreeding. Mouse tail samples were used for
genotyping the presence of the Cre transgene and the
floxed C/EBPβ alleles. DNA was extracted and purified
using KAPA Mouse Genotyping Kit (Kapa Biosystems).
One microliter of the supernatant was used for polymerase
chain reaction (PCR) amplification with specific primers
for the LysMCre (5′-CCCAGAAATGCCAGATTACG-3′
mutant, 5′-CTTGGGCTGCCAGAATTTCTC-3′ com-
mon, 5′-TTACAGTCGGCCAGGCTGAC-3′ wild type)
as described in the JAX mouse database (The Jackson
Laboratory) and the C/EBPβ floxed allele (forward: 5-
GAGCCACCGCGTCCTCCAGC-′3′, reverse: 5′-GGT
CGGTGCGCGTCATTGCC-3′). PCR products were
loaded on 2% agarose gels to check the presence (700 bp)
or absence (350 bp) of the LysMCre transgene and the
wild-type (240 bp) or floxed (320 bp) C/EBPβ allele. The
mice were breed and housed under specific pathogen-free
conditions in the animal facilities at the School of
Medicine, University of Barcelona.
Primary microglial cultures
Microglial cells were isolated from primary mixed glial
cultures prepared from P1-P3 C/EBPβfl/fl and LysMCre-
C/EBPβfl/fl mice. The brains were dissected, the meninges
removed and the cortices digested with 0.25% trypsin for
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30 min at 37 °C. Trypsinization was stopped by adding an
equal volume of culture medium (Dulbecco’s modified
Eagle’s medium-F-12 nutrient mixture, fetal bovine
serum 10%, penicillin 100 U/mL, streptomycin 100 μg/mL
and amphotericin B 0.5 μg/mL) with 160 μg/mL deoxy-
ribonuclease I (all from Invitrogen or Sigma) and brought
to a single cell suspension by repeated pipetting followed
by passage through a 100-μm pore mesh. The solution
was pelleted (7 min, 200 g) and resuspended in culture
medium. Glial cells were seeded at a density of 3.5 × 105
cells/mL and cultured at 37 °C in humidified 5% CO2–
95% air. Medium was replaced once a week. Microglial
cultures were prepared from DIV19-21 mixed glial cul-
tures by the mild trypsinization method [12] and used
24 h after isolation.
Ex vivo isolation of adult microglia
Microglial cells were acutely isolated from male adult
mouse brains as described [13]. Briefly, mice were deeply
anesthetized with isofluorane, perfused transcardially
with ice-cold PBS + 10 U/ml heparin and the brains
dissected and dissociated by trypsin digestion as described
in the “Primary microglial cultures” section. Dissociated
cells were then resuspended in 30% Percoll (GE Healthcare)
and centrifuged for 10 min at 700g. The myelin-containing
supernatant was removed, and the pelleted cells were
washed twice with ice-cold PBS. Cells were then incubated
with 10 μl CD11b Microbeads (Miltenyi Biotec) and 90 μl
buffer (PBS supplemented with 0.5% BSA and 2 mM
EDTA) for 15 min at 4 °C. After washing, CD11b+ cells
were separated in a magnetic field using MS columns
(Miltenyi Biotec). The CD11b+ fraction was collected
and used for further analyses. The yield was 379.415 ±
79.073 (SD, n = 48) microglial cells per brain.
In vivo systemic lipopolysaccharide (LPS) injection
Systemic LPS injection was used as an in vivo model of
acute neuroinflammatory response. Eight-week-old male
mice were injected i.p. with 4 mg/kg LPS (055:B5,
Sigma-Aldrich; 100 μl per animal) or vehicle (PBS), and
microglia was isolated 16 h after LPS injection as de-
scribed above.
Experimental autoimmune encephalomyelitis
EAE, an animal model of multiple sclerosis, was used to
analyze the effect of microglial C/EBPβ deficiency in an
in vivo model of a neurological disorder. LysMCre, C/
EBPβfl/fl and LysMCre-C/EBPβfl/fl 7–8-week-old female
mice were used. Under isofluorane anesthesia, the animals
were subcutaneously injected at two sites into the flanks with
200 μl of a freshly prepared immunization cocktail contain-
ing myelin oligodendrocyte glycoprotein peptide (MOG35-
55; Sigma; 100 μg/mouse), complete Freund’s adjuvant
(Sigma) and Mycobacterium tuberculosis (H37R; Difco;
1 mg/mouse). Control mice received immunization cocktail
without MOG35-55. Immediately after immunization and
2 days later, mice were injected i.p. with Bordetella pertussis
toxin (Sigma, 500 ng/mouse). Mice were weighed and scored
daily from day 8 post-immunization in a blind manner
according to the following scale: 0, no deficit; 1, tail
paralysis; 2, hind limb paresis; 3, incomplete hind limb
paralysis; 4, complete hind limb paralysis; and 5, moribund
state or death. Wet food was supplied when score 2 was
reached and 200 μL of saline was administrated subcutane-
ously when animals scored 4. For comparison of EAE pro-
gression among genotypes, mice were scored until 52 days
post-immunization at which point they were sacrificed. For
analysis of C/EBPβ messenger RNA (mRNA) and protein
expression in EAE, CFA- and MOG35-55-treated wild-
type mice were sacrificed at various time-points post-
immunization (9, 14, 21 and 28 days). The spinal cords
were dissected into cervical, thoracic and lumbar regions,
whereas the brains were dissected into hindbrain, mid-
brain and forebrain. Tissue samples were quickly frozen
and stored at −80 °C.
Immunocytochemistry
Cultured cells were fixed with 4% paraformaldehyde in
PBS for 20 min at RT. After permeation with chilled
methanol for 7 min and three PBS rinses, cells were
incubated overnight at 4 °C with the primary antibody
diluted in 7% normal goat serum (Sigma) in PBS con-
taining 0.01% sodium azide. After rinsing in PBS, cells
were incubated for 1 h at RT with secondary antibody
and DAPI (5 μg/mL). The primary antibodies were
monoclonal mouse anti-C/EBPβ (1:500, Abcam, ab-18336),
polyclonal rabbit anti-nitric oxide synthase 2 (NOS2)
(1:400, BD Transduction Laboratories, 610333), polyclonal
rabbit anti-GFAP (1:1000, DakoCytomation, Z0334), poly-
clonal rabbit anti-Iba1 (1:1000, Wako, 019-19741) and
monoclonal rat anti-CD11b (1:300, Serotec, MCA711G,
clone 5C6). The secondary antibodies were goat anti-
mouse Alexa 546 (1:1000, Molecular Probes, A-11018),
Alexa 488 (1:1000, Molecular Probes, A11017), goat anti-
rabbit, Alexa 488 (1:1000, Molecular Probes, A-11070)
and goat anti-rat Alexa 546 (1:1000, Molecular Probes,
A11081). Microscopy images were obtained with an
Olympus IX70 microscope and a digital camera (CC-12,
Soft Imaging System GmbH).
Cytospin
25.000 microglial cells from one adult mouse brain isolated
as described in the “Ex vivo isolation of adult microglia”
section were centrifuged for 5 min at 1000 rpm at RT using
Shandon Cytospin 4 (Thermo Scientific) and collected in
gelatinized slides. Cells were then fixed with 4% paraformal-
dehyde in PBS for 20 min at RT and washed three times in
PBS. After blocking for 30 min at RT with PBS containing
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1% BSA, 0.03% Triton and 10% normal donkey serum
(Gibco), cells were incubated overnight at 4 °C with
primary antibodies diluted in blocking solution. After
washing in PBS, slides were incubated for 1 h at RT
with secondary antibodies and DAPI (5 μg/mL) diluted
in blocking solution. The primary antibodies were mono-
clonal mouse anti-C/EBPβ (1:1111, AbCam, ab-18336) and
monoclonal rat anti-CD68 (1:1000, Serotec, MCA1957).
The secondary antibodies were donkey anti-mouse Alexa
546 (1:1000, Molecular Probes, A21203) and goat anti-rat
Alexa 488 (1:1000, Molecular Probes, A21208). Microscopy
images were taken with a Nikon Eclipse E 1000 microscope
and a digital camera Olympus DP72.
Histology
C/EBPβfl/fl and LysMCre-C/EBPβfl/fl 10-week-old female
mice were deeply anesthetized with isofluorane and per-
fused transcardially with ice-cold 4% paraformaldehyde
in PBS. The brain, lung, heart, mammary gland, spleen,
liver, lung, kidney, femur bone and lumbar vertebrae
were carefully dissected. Initial examination of macroscopic
appearance of the organs was performed by reporting any
gross anormality. Tissue specimens were formalin-fixed,
paraffin-embedded using routine procedures and then cut
into 5-μm semi-serial sections. Every fifth slide was stained
with haematoxylin and eosin and examined under light
microscope.
NO determination
Primary microglial cultures from C/EBPβfl/fl and LysMCre-
C/EBPβfl/fl mice were treated with LPS (100 ng/mL) with
or without IFNγ (0.1, 1, 10 or 30 ng/mL) for 48 h. NO pro-
duction was assessed by detecting accumulation of nitrites
in the conditioned medium by the Griess colorimetric
assay, as described [12].
Isolation of total proteins and Western blot
Total microglial proteins were isolated by lysing pelleted
cells from one 75 cm2 flask of primary microglial cul-
tures per treatment condition (LPS 100 ng/mL with or
without IFNγ 1 ng/mL for 24 h) and CD11b+ cells iso-
lated from one adult brain as described in the “Ex vivo
isolation of adult microglia” section with 50 μL of RIPA
buffer (containing Igepal CA-630 (10 μL/mL), sodium
deoxycholate (5 mg/mL), SDS (1 mg/mL) and protease
inhibitor cocktail Complete®, in PBS. Protein amount
was determined by the Bradford assay, and protein
samples (20 μg) were denatured (5 min 95 °C), resolved
by SDS-PAGE on 12% gels and transferred to a PDVF
membrane. Membranes were incubated overnight at 4 °C
with primary anti-C/EBPβ antibodies of mouse origin
(Abcam, ab18336; for primary cultured microglia proteins)
or rabbit origin (Abcam, ab32358; for acutely isolated
adult microglia proteins) diluted in both cases 1:500 in
immunoblot buffer (Tris-buffered saline (TBS) containing
0.05% Tween-20 and 5% nonfat dry milk). Following three
TBS-0.05% Tween-20 rinses, HRP-labelled anti-mouse
(1:2000, Santa Cruz, sc-2055) and anti-rabbit (1:15000, GE
Healthcare, NA934) secondary antibodies were incubated
for 45 min at RT. To label the loading control protein,
monoclonal mouse anti-β-actin-peroxidase (1/40000,
Sigma, A3854) was incubated for 20 min at RT. Pro-
teins were visualized with WesternBright™ Quantum-ECL
(Advansta) and membranes exposed to Agfa Curix RP2
Plus films. Data are expressed as the ratio between the
intensity of the C/EBPβ band and the loading control
protein band (β-actin). For Western blot with EAE and
human postmortem samples, the same protocol was
used with the exception that the primary antibody
was co-incubated with an enhancer solution (Signal
Boost™Immunoreaction Enhancer Kit, Merck).
Total RNA extraction and qRT-PCR
Isolation of total RNA from microglial cell cultures was
performed by lysing pelleted cells from one 75 cm2 flask
per treatment condition (LPS 100 ng/mL with or with-
out IFNγ 1 ng/mL for 6 h) with 1 mL of TriReagent
(Sigma) and 100 μl of 1-bromo-3-chloropropane (BCP,
Sigma). The aqueous phase containing total RNA was
recovered after centrifugation for 15 min at 12.000g at
4 °C, mixed with an equal volume of ice-cold 70% ethanol
and loaded onto a PureLink™Micro Kit column (Invitrogen).
Total RNA was then purified following manufacturer’s
instructions. Isolation of total RNA from adult micro-
glial cells was carried on after pelleting CD11b+ cells
isolated from one adult brain as described in the “Ex
vivo isolation of adult microglia” section, using Pure-
Link™ Micro Kit (Invitrogen) following manufacturer’s
instructions. Isolation of total RNA from spinal cord
(cervical, thoracic and lumbar) and brain (mesenceph-
alon plus diencephalon, rhombencephalon and telen-
cephalon) samples of EAE mice was performed using
Trizol method (Tri®Reagent, Sigma-Aldrich). Total
RNA was quantified spectrophotometrically with Nano
Drop ND-1000 (Thermo Scientific). Reverse transcription
reactions were carried out from 300 ng (cultured cells) or
1 μg (tissue) of total RNA with random primers using
Transcriptor Reverse Transcriptase (Roche). Complemen-
tary DNA (cDNA) was diluted 1/30, and 3 μl were used to
perform qRT-PCR with qPCRBIO Sygreen Mix Lo-ROX
(PCB-P20.11-50, Vitro) in 15 μl of final volume reaction
using CFX96 Thermal Cycler equipment (Bio-Rad). Mea-
surements were performed in duplicates. Primers, shown
in Table 1, were used at final concentration of 300 nM.
Samples were run for 45 cycles (95 °C for 30 s, 60 °C or
62 °C for 1 min and 72 °C for 30 s). Amplification specifi-
city was confirmed by the analysis of melting curves, and
relative gene expression values were calculated using Bio-
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Rad CFX Managing software (Bio-Rad) with the compara-
tive Ct or ΔΔCt method.
Viability
Microglial cell cultures from C/EBPβfl/fl and LysMCre-
C/EBPβfl/fl mice were treated with LPS 1 μg/mL with or
without IFNγ 1 or 30 ng/mL. Cells were fixed (0, 3, 5 or
7 days post-treatment) and probed as described in the
“Immunocytochemistry” section. DAPI and Iba1-positive
cells were manually counted using ImageJ software. In
every experiment (n = 3), three wells per condition and
three fields per well were analyzed. Results are repre-
sented as percentage of live cells on day 0.
Phagocytosis
The Salmonella enterica serovar Typhimurium (S. typhi-
murium) SV5015 strain, a His+ derivative of the SL1344
strain (mouse-virulent) [14], was transformed with the
pBR.RFP.1 plasmid [15] to render red autofluorescent
bacterial cells. To test microglia phagocytic capacity, first,
microglial cell cultures from C/EBPβfl/fl and LysMCre-C/
EBPβfl/fl mice were treated with LPS 100 ng/mL with or
without IFNγ 1 ng/mL in antibiotic-free culture medium.
Twenty-four hours after treatment, microglia were in-
fected with S. typhimurium for 30 min at multiplicity of
infection of 5, defined as the ratio of bacteria per cultured
cell. Non-ingested bacilli were eliminated by washing
three times with PBS. Cells to assess phagocytic activity
were then fixed as described in the “Immunocytochem-
istry” section, whereas to study resolution of infection,
microglial cells were further incubated for 1 h in medium
containing 100 μM gentamicin (Sigma-Aldrich) to kill
extracellular bacteria and then switched to medium with a
lower dose of gentamicin (10 μM) for 3 h before fixation.
Cells were immunostained for Iba1 as described in the
“Immunocytochemistry” section. Intracellular autofluores-
cent bacteria were manually counted using the ImageJ
software along with DAPI and Iba1-positive cells. In every
experiment (n = 3), two wells for each condition and three
fields per well were analyzed. Results are represented as
percentage of infected microglial cells and number of bac-
teria phagocytosed at 0.5 and 4 h post Salmonella infection.
RNA sequencing (RNAseq)
Total RNA from primary microglia was isolated as
described in the “Total RNA extraction and qRT-PCR”
section. Total RNA integrity and quality were assessed
with the Bioanalyzer 2100 system (Agilent). Library prepar-
ation and ultrasequencing were performed following Illumi-
na’s (San Diego, CA) protocols. First, transfer RNA (tRNA)
and ribosomal RNA (rRNA) were removed from 1 μg of
total RNA using TruSeq Stranded Total RNA Sample Prep
Kits (Illumina). Then, the RNA pool (mRNA + miRNA +
lncRNA + other RNAs) was fragmented into pieces of ap-
proximately 200 bp using divalent cations under elevated
temperature. The cleaved RNA fragments were reverse-
transcribed into first-strand cDNA using reverse tran-
scriptase and random primers. Next, the second strand
was synthesized using DNA polymerase I and RNAse
H. These double-stranded cDNA fragments were end-
repaired by T4 DNA polymerase and Klenow DNA
polymerase, and phosphorylated by T4 polynucleotide
kinase. The cDNA products were incubated with Klenow
DNA polymerase to generate 39 adenine overhangs, there-
fore allowing ligation to Illumina indexing adapters to the
double-stranded cDNA ends. The adapter-ligated products
were purified with Ampure XP magnetic beads (Agencourt
Bioscience Corporation, Beverly, MA, USA), and libraries
were amplified by 15 cycles of PCR with Phusion DNA
polymerase (Finnzymes Reagents, Vantaa, Finland). Con-
structed libraries were validated and quantified using Bio-
Rad’s automated electrophoresis system Experion and
qRT-PCR, respectively. Pools of six indexed libraries
were mixed (multiplexed) at equimolar ratios to yield a
total oligonucleotide mix concentration of 10 nM. Finally,
the resulting libraries were sequenced on the Genome
Analyzer IIx platform (Illumina) to generate 150 bp single
reads. Six pooled indexed libraries were sequenced in each
flow cell lane. Raw sequence (FASTQ format) were
processed through a series of sequential steps: (1) ag-
gressive adapters removal; (2) alignment/mapping of
RNA sequences to the mouse genome reference (Mus_
musculus.mm10) using tophat software; and (3) sorting
and cataloguing of the results by using Samtools soft-
ware [16] in Bam files.
RNAseq statistic and bioinformatic analyses
Bam files of RNA readings were processed using the
Rsubread package [17] in the R environment and aligned
to the mm10 version of mouse genome with the func-
tion featureCounts [18]. Summarized readings by gene
were then normalized using voom normalization [19] to
fit the count matrix into linear modelling with the
Table 1 Primers used in this study
Gene Forward Reverse
Cebpb AAG CTG AGC GAC GAG TAC
AAG A
TCA GCT CCA GCA CCT TGT G
Il23a TGT GCC CCG TAT CCA GTG TG AAA AGC CAG ACC TTG GCG GA
Cybb ACT CCT TGG GTC AGC ACT GGC GCA ACA CGC ACT GGA ACC CCT
Tnfα TGA TCC GCG ACG TGG AA ACC GCC TGG AGT TCT GGA A
Ptges AGG CCA GAT GAG GCT GCG GA AGC GAA GGC GTG GGT TCA GC
Csf3 AGA GCT GCA GCC CAG ATC ACC AGC TGC AGG GCC ATT AGC
TTC A
Rn18s GTA ACC CGT TGA ACC CCA TT CCA TCC AAT CGG TAG TAG CG
Hprt1 ATC ATT ATG CCG AGG ATT TGG GCA AAG AAC TTA TAG CCC CC
Sdha TGG GGA GTG CCG TGG TGT CA CAT GGC TGT GCC GTC CCC TG
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package limma [20]. Normalized whole read counts were
used to cluster samples with package hcluster using
standard hierarchical cluster with average linkage. A lin-
ear fit model algorithm was used to obtain differentially
expressed genes (DEGs) that complied with p < 0.01 and
fold change >2. DEGs by comparison were summarized
using the VennDiagram package. Heatmap visualization
and clustering of DEGs was done with Genesis software
after expressing gene values in standard deviation and
using hierarchical clustering with average linkage by
genes and samples. Finally, Genecodis [21] tools were
used to obtain Gene Ontology and Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway terms enrich-
ment using the adjusted p value <0.01 after a hypergeo-
metric test. Reads per kilobase per million mapped reads
(RPKM) filtered values (sum of RPKM> 2 for each gene)
were introduced to the Weighted Correlation Gene Net-
work Analysis (WGCNA) package in R, to perform
WGCNA as previously described [22]. Combined sam-
ples were surveyed and measured with the pickSoft-
Threshold function to obtain a correct power β
considering the smallest value to give a free-scale top-
ology. Using 9 as the power value, the blockwise func-
tion was used with parameters mergeCutHeight = 0.001
and detectCutHeight = 0.995 to obtain 34 modules code-
named by color, containing genes with high co-
expression similarity. Module relationship with traits:
treatment (Vehicle = 0; LPS = 1; LPS + IFNγ = 2) and
genotype (C/EBPβfl/fl = 0; LysMCre-C/EBPβfl/fl = 1) was
also calculated for each module to obtain a correlation.
Gene symbols and normalized values were appended, and
heatmap visualization of individual modules was obtained
within the WGCNA package in R. Finally the Metacore™
platform was used to obtain the described interactions of
proteins among the different modules to produce “external
knowledge networks”, while VisAnt software was used with
the correlation values in our experiments to produce the
specific network of correlation within our data. For the
separate analysis of DEGs in each experimental condi-
tion, samples of each group (control, LPS, LPS + IFNγ)
were used in a separate pipeline, then a linear fit algo-
rithm with Bayesian correction was applied grouping
biological replicates of samples and designing a contrast
matrix that compared genotypes selecting genes which
complied with criteria fold change > 2, adjusted p < 0.05
(Benjamini–Hochberg procedure) as sample number
was lower and power diminished for these analyses.
DEGs in these lists were mostly in agreement with the
whole comparison matrix DEGs.
Statistics
Statistical analyses of RNAseq data are described in the
“RNA sequencing (RNAseq)” section. For other parts of
the study, statistical analyses were performed using one-
way ANOVA followed by Newman–Keuls post hoc test
when three or more experimental groups were compared.
When the effect of treatment on genotype or the opposite
were studied, two-way ANOVA followed by Bonferroni
post-test was used. Non-parametric measures (EAE scores)
were analyzed with Kruskal–Wallis test and Dunn’s
multiple comparison post-test. Values of p < 0.05 were
considered statistically significant. Results are repre-
sented as mean ± standard error of the mean (SEM).
Experimental data were analyzed using GraphPad Prism
5.01 software.
Results
Characterization of LysMCre-C/EBPβfl/fl mice and their
microglia in primary culture
LysMCre-C/EBPβfl/fl mice had normal appearance and
body weight (Fig. 1a) and showed no obvious behavioral
abnormalities when compared to wild type, LysMCre or
C/EBPβfl/fl mice. Their survival rate and fertility were
normal in contrast to what has been reported in C/EBPβ
knockout mice [23]. Litter size and gender distribution
were also normal. Histological evaluation of haematoxylin
and eosin stained sections (Fig. 1b) showed normal mam-
mary gland and red and white spleen pulp morphology,
again in contrast to reports in mice with ubiquitous C/
EBPβ deficiency [23]. No differences between genotypes
were observed in all other tissues and organs examined,
listed in the online methods section.
Western blot analysis of proteins from primary microglial
cultures showed robust C/EBPβ expression in C/EBPβfl/fl
microglia, and this expression was enhanced by LPS + IFNγ
treatment (Fig. 2a). Interestingly, C/EBPβ proteins were not
detected in primary microglia from LysMCre-C/EBPβfl/fl
mice, neither in control nor after LPS + IFNγ treatment
(Fig. 2a, b). Immunocytochemical C/EBPβ staining con-
firmed this finding. In control conditions, C/EBPβ was
present in most microglial cells in primary cultures from
C/EBPβfl/fl mice, and the number of positive cells and the
intensity of the staining was enhanced by LPS + IFNγ
treatment (24 h). In contrast, microglia from LysMCre-C/
EBPβfl/fl mice were devoid of C/EBPβ immunostaining,
both in control and LPS + IFNγ conditions (Fig. 2c).
These findings show that the efficiency of LysMCre-
induced recombination of C/EBPβ LoxP sites in primary
microglia from LysMCre-C/EBPβfl/fl mice is near 100%.
C/EBPβ immunocytochemistry of mixed glial cultures
confirmed the absence of C/EBPβ in LysMCre-C/EBPβfl/fl
microglia, identified by Iba1 immunostaining (Fig. 2e),
and showed the presence of normal levels of C/EBPβ im-
munostaining in astrocytes, identified by GFAP (Fig. 2d),
thus supporting the specificity of LysMCre-induced re-
combination in microglia.
We were next interested in determining whether the
absence of C/EBPβ affects microglial function. To this
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end, we assessed NO production and NOS2 expression,
activation-induced cell death (AICD) and phagocytosis
of bacterial cells by primary microglial cultures from C/
EBPβfl/fl and LysMCre-C/EBPβfl/fl mice. NO production
is a key element in pro-inflammatory microglial activa-
tion and others, and we showed its regulation by C/
EBPβ in microglia [3, 24]. In primary microglial cultures
from C/EBPβfl/fl mice, co-treatment of LPS with IFNγ
induced a dose-dependent increase in NO production
which was markedly attenuated in LysMCre-C/EBPβfl/fl
microglia (Fig. 3a). We then assessed by immunocyto-
chemistry the expression of NOS2, the NO producing
enzyme in activated microglia, in mixed glial cultures
from both genotypes in control and LPS + IFNγ
conditions. NOS2 was undetectable in control condi-
tions, but it was induced by LPS + IFNγ in C/EBPβfl/fl
glial cultures, and this response was markedly attenuated
in LysMCre-C/EBPβfl/fl cultures (Fig. 3b). CD11b immu-
nostaining revealed the microglial nature of NOS2-
expressing cells in activated mixed glial cultures. In this
experiment, we could not use Iba1 as microglial marker
because both anti-Iba1 and anti-NOS2 antibodies were
from a rabbit. These findings provide a first indication of
an attenuated pro-inflammatory response in microglia
from LysMCre-C/EBPβfl/fl mice.
Overactivation of microglia leads to apoptotic cell
death in a process named AICD thought to contribute
to maintaining low numbers of activated microglia after
brain damage [25]. The role of C/EBPβ in microglial
AICD has not been studied, but since C/EBPβ regulates
microglial NO production and NO is an important
AICD effector in microglia, we hypothesized that AICD
could be attenuated in C/EBPβ-deficient microglia. In C/
EBPβfl/fl microglia, LPS induced a clear AICD effect (40%
cell death, 5 days) that was markedly potentiated by IFNγ
(90% cell death, 5 days) (Fig. 3c). The same effect was ob-
served in LysMCre-C/EBPβfl/fl microglia thus ruling out a
key role for C/EBPβ in microglial AICD. Similar results
were obtained 3 and 7 days after treatments (data not
shown).
We were finally interested to study the role of C/EBPβ
in phagocytosis, one of the major physiological roles of
microglia. To this end, control and activated microglia
from both genotypes were incubated with autofluores-
cent S. typhimurium, a Gram-negative bacterium. The
percentage of infected microglia and the number of bac-
teria per microglial cell were assessed 30 min and 4 h
after addition of bacteria. Data obtained in 30 min indi-
cate phagocytic capacity whereas data in 4 h show the
ability of microglia to eliminate phagocytosed bacterial
cells. As shown in Fig. 3d, 30 min after bacteria addition,
no differences in phagocytosis between both genotypes
were observed in untreated microglia. However, after LPS +
IFNγ treatment, LysMCre-C/EBPβfl/fl microglia showed
higher number of infected cells and higher intake of bacteria
per cell than C/EBPβfl/fl microglia, whereas after LPS
treatment, LysMCre-C/EBPβfl/fl microglia showed higher
number of phagocytosed bacteria per cell. Four hours after
bacteria addition, differences between both genotypes were
attenuated. Only in LysMCre-C/EBPβfl/fl microglia treated
with LPS + IFNγ there was an increase in the percentage of
infected cells, but of lower magnitude than that observed in
30 min. In C/EBPβfl/fl microglia, the percentage of infected
cells and the number of bacteria/cell in 4 h were not
decreased when compared with the 30 min values, with
only one exception (% infected cells after LPS treat-
ment). In contrast, in LysMCre-C/EBPβfl/fl microglia,
the percentage of infected cells and the number of
Fig. 1 Phenotypic characterization of LysMCre-C/EBPβfl/fl mice. a
Body weight curves of female C/EBPβfl/fl (n = 10) and LysMCre-C/
EBPβfl/fl (n= 6) mice shown as mean ± SEM. No significant differences in
body weight are observed between both genotypes. b Representative
microscopic images of haematoxylin and eosin staining of the mammary
gland and spleen from 10-week-old C/EBPβfl/fl and LysMCre-C/EBPβfl/fl
mice. Normal ductal development and branching as well as unaltered
adipose tissue in mammary gland from both genotypes are noted.
Normal morphology of red and white pulps and megakaryocytes
(insets) are also seen in both genotypes. No histological differences
are observed also in the brain, lung, heart, liver, lung, kidney, femur
bone and lumbar vertebrae (not shown). Scale bars 100 μm (large
images) and 50 μm (insets)
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bacteria/cell in 4 h were decreased vs 30 min (with one
exception: bacteria/cell after LPS + IFNγ treatment).
These data demonstrate increased phagocytic activity
and higher capacity to eliminate phagocytosed bacteria
of C/EBPβ-deficient microglia.
C/EBPβ-deficient cultured microglia show marked
changes of gene expression
After demonstrating the widespread deficiency of C/
EBPβ in microglia from LysMCre-C/EBPβfl/fl mice and
its functional effects, we assessed the global effects of
Fig. 2 Reduced C/EBPβ protein in LysMCre-C/EBPβfl/fl microglia in culture. a Representative Western blot showing C/EBPβ LAP protein levels in
primary microglial cultures from C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice treated with vehicle (C) or LPS (100 ng/mL) + IFNγ (1 ng/mL) (L + I) for
24 h. Detection of the C/EBPβ isoforms Full and LIP in these samples required longer exposure. b Quantification of Western blot signals from four
independent experiments as that shown in a. C/EBPβ protein levels are normalized using β-actin levels. Data are shown as mean + SEM. Significant
effect of treatment is observed in C/EBPβfl/fl microglia (**p < 0.01), and significant effect of genotype is observed both in vehicle- and LPS + IFNγ-
treated microglia (###p < 0.001). c Primary microglial cultures were treated as in a, fixed and C/EBPβ protein was analyzed by immunocytochemistry
and nuclei were counterstained with DAPI. Note the nuclear C/EBPβ expression in virtually all microglial cells in C/EBPβfl/fl cultures which is enhanced
by LPS + IFNγ and the complete absence of C/EBPβ immunoreactivity in LysMCre-C/EBPβfl/fl microglial cells in culture. Scale bar 100 μm. d, e Primary
mixed glial cultures containing mainly astrocytes and microglia were treated as in a, fixed, immunostained for C/EBPβ (red) and the astroglial marker
GFAP (green in d) or microglial marker Iba1 (green in e) and counterstained with DAPI. In C/EBPβfl/fl cultures, C/EBPβ immunostaining is observed in
both GFAP-positive cells (astrocytes; arrows) and Iba1-positive cells (microglia; arrowheads), whereas in LysMCre-C/EBPβfl/fl cultures, C/EBPβ is only
observed in astrocytes. Scale bar 50 μm
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Fig. 3 (See legend on next page.)
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C/EBPβ deficiency in microglial gene expression by com-
paring by RNAseq the transcriptomic profiles of C/EBPβfl/fl
and LysMCre-C/EBPβfl/fl primary microglial cultures
treated with vehicle, LPS or LPS + IFNγ for 6 h.
RNA libraries and sequencing where prepared as de-
scribed in the “Methods” section. Unsupervised cluster
analysis using normalized counts (RPKM) showed a
strong effect of treatments on microglial RNA expres-
sion. The 21 samples were grouped in three clusters
corresponding without exception to microglial cultures
treated with vehicle (n = 7), LPS (n = 7) and LPS + IFNγ
(n = 7) (Fig. 4a). The clustering analysis also revealed a
marked effect of genotype on RNA expression, particularly
in activated microglia. Thus, LPS- and LPS + IFNγ-treated
samples were subclassified into two clusters corresponding
to genotypes C/EBPβfl/fl and LysMCre-C/EBPβfl/fl microglia
(Fig. 4a). This analysis strongly suggests that C/EBPβ plays
an important role in the regulation of gene expression in
activated microglia. Afterwards, the validated pipeline for
differentially expressed genes (DEGs) detection Rsubread/
voom normalization/limma [20] was used selecting
genes that complied with fold change >2 and p < 0.01
(Benjamini–Hochberg method for multiple comparisons)
in pairs of conditions compared. Out of 15228 genes with
significant RNA expression in microglia, 1068 were affected
by C/EBPβ deficiency. As the Venn diagram in Fig. 4b
shows, most of these were genes also significantly affected
by LPS (717 genes) or LPS + IFNγ (708 genes) and only
201 of C/EBPβ-dependent genes were unaffected by LPS or
LPS + IFNγ again indicating a major role for C/EBPβ on
gene expression in activated microglia. In addition, we
separately analyzed the samples to show the DEG
between C/EBPβfl/fl and LysMCre-C/EBPβfl/fl microglia
in each treatment condition (Control, LPS, LPS + IFNγ).
In control conditions C/EBPβ absence resulted in more
genes being downregulated (44 genes) than upregulated
(13 genes); in the LPS condition the opposite was observed
(459 upregulated and 339 downregulated); and in the
LPS + IFNγ condition the number of upregulated and
downregulated genes was similar (197 and 217 genes,
respectively) (Additional file 1: Tables S1–S6).
DEGs log2 values of C/EBPβfl/fl and LysMCre-C/EBPβfl/fl
comparison (n = 1068) were normalized to be expressed in
standard deviation values (±3 SD) and represented on a
heatmap (Fig. 4c). A hierarchical cluster algorithm for
samples and genes revealed two sample clusters: cluster
1 which included untreated samples of both genotypes
and treated LysMCre-C/EBPβfl/fl samples and cluster 2
which included treated C/EBPβfl/fl samples. This shows
that LPS ± IFNγ-treated LysMCre-C/EBPβfl/fl microglia
have an attenuated phenotype with a gene expression
profile closer to untreated microglia than to treated C/
EBPβfl/fl microglia. This analysis also shows a neat separ-
ation of untreated samples into two clusters correspond-
ing to the two genotypes demonstrating in an unbiased
way the altered biology of C/EBPβ-deficient microglia in
basal conditions. Additionally, a Weighted Correlation
Gene Network Analysis (WGCNA) was performed, separ-
ating all 15,228 genes into 35 modules. The dendrogram
of WGCNA revealed a large grouping of genes corre-
sponding to module “turquoise” which represent genes
with decreased expression upon LPS or LPS + IFNγ treat-
ments (Additional file 2: Figure S1A). Complementarily,
dendrogram clustering of modules highlighted module
“violet” as the closest group of genes correlating with
genotype differences (Additional file 2: Figure S1B). Mod-
ule violet contained C/EBPβ as expected (Additional file 2:
Figure S1C) and additionally a set of genes linked by outer
literature databases (Metacore™; Additional file 2: Figure
S1D) and within the distance measures of experiment data
(Additional file 2: Figure S1E).
Finally, we used the Genecodis platform [21] to obtain
DEG enrichment in different annotation databases, spe-
cifically for Gene Ontology (GO) terms for Biological
(See figure on previous page.)
Fig. 3 LysMCre-C/EBPβfl/fl microglial function in culture. a Primary microglial cultures from C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice were treated
with vehicle (C), LPS (100 ng/mL) ± IFNγ (0.1, 1, 10, 30 ng/mL) for 48 h. NO production was estimated by measuring nitrites in the conditioned
medium by the Griess reaction. Data show mean + SEM of six independent experiments. Asterisks show the significance of the treatment
effect (**p < 0.01; ***p < 0.001 compared with the respective control conditions) and number sign shows the significance of the genotype
effect (##p < 0.01; ###p < 0.001 compared with the respective C/EBPβfl/fl condition). b Mixed glial cultures from C/EBPβfl/fl and LysMCre-C/
EBPβfl/fl mice were treated for 24 h with vehicle (C) or LPS (100 ng/mL) + IFNγ (1 ng/mL) and processed for immunocytochemistry for
NOS2 (green), the microglial marker CD11b (red) and the nuclear counterstain DAPI (blue). LPS-induced NOS2 expression in C/EBPβfl/fl
cultures is markedly attenuated in LysMCre-C/EBPβfl/fl cultures. NOS2 expression is always microglial as revealed by CD11b colocalization.
Arrows show NOS2-positive cells. Scale bar, 100 μm. c Primary glial cultures from C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice were treated with
vehicle (C), LPS (100 ng/mL) ± IFNγ (1 and 30 ng/mL). Five days after treatment, Iba1-positive microglial cells were counted as indicated in
the “Methods” section. Data represent the percentage of microglial cells on day 0 shown as mean + SEM of three independent experiments. Note the
marked AICD effect induced by LPS and particularly by LPS + IFNγ and the absence of differences between the two genotypes. d Primary microglial
cell cultures from C/EBPβfl/fl and LysMCre C/EBPβfl/fl mice were treated with vehicle (C), LPS (100 ng/mL) or LPS + IFNγ (1 ng/mL) for 24 h prior to
infection with fluorescent Salmonella for 30 min. Microglial cultures were fixed immediately (white bars) or 4 h later (black bars), and the percentage of
infected microglial cells and the number of bacteria phagocytosed were analyzed. Data show mean + SEM of three independent experiments. The
asterisk shows the significance of the differences between 30 min and 4 h (*p < 0.05; **p < 0.01 compared with the respective 30-min value) and the
number sign shows the significance of the genotype effect (#p < 0.05; ##p < 0.01; ###p < 0.001 compared with the respective C/EBPβfl/fl condition)
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Process (Fig. 5a), and for the Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways (Fig. 5b). Not-
ably, various GO categories and KEGG pathways re-
lated to inflammatory and innate immune responses
were among the most significantly represented (e.g.
inflammatory response, GO:0006954; Fig. 5c). Interest-
ingly, lysosome and phagosome KEGG pathways were
also particularly represented (Fig. 5d–f ).
Fig. 4 Treatment with LPS ± IFNγ (6 h) evidences differential transcriptomic changes between C/EBPβfl/fl and LysMCre-C/EBPβfl/fl microglia.
a Hierarchical clustering of total RNASeq RPKM normalized values separate samples neatly by treatment. Remarkably, C/EBPβfl/fl and LysMCre C/EBPβfl/fl
groups are mixed in the control condition, but separate into subgroups once any treatment is applied to microglia (Euclidean distance). b Linear model
fitting of filtered genes (RPKM sum of genes through samples >2) detects 10,888 genes as differentially expressed (DEGs) (lfc > 1, adjusted p value <0.01
Benjamini–Hochberg correction). Contrasts between groups are shown on the Venn diagram. More specifically, 1068 genes are detected as DEGs for the
C/EBPβfl/fl vs LysMCre-C/EBPβfl/fl contrast. c Heatmap of C/EBPβfl/fl and LysMCre-C/EBPβfl/fl DEGs (n= 1068) with applied hierarchical clustering (average
linkage, Euclidean distance). Values are represented as SD from the normalized average for each gene. Sample clustering evidences three main groups;
with cluster 1 (pink) corresponding to the control condition which contain subclusters separating C/EBPβfl/fl and LysMCre-C/EBPβfl/fl. Remarkably, clusters
2 (magenta) and 3 (purple) correspond to C/EBPβfl/fl and LysMCre-C/EBPβfl/fl conditions and contain subclusters organized by treatment. On the other
hand, gene cluster classification (A–M) evidences the combination of patterns of expression among samples. In this figure, WT and KO refer to C/EBPβfl/fl
and LysMCre-C/EBPβfl/fl, respectively
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In summary, this analysis shows the importance of
microglial C/EBPβ, since its deletion affects the expression
of 1068 genes. It confirms the involvement of C/EBPβ in
the regulation of pro-inflammatory programs in activated
microglia, but it also reveals a role of C/EBPβ in other
programs such as phagocytosis and apoptosis. Interest-
ingly, it reveals for the first time a role for C/EBPβ in non-
stimulated microglia.
Robust C/EBPβ deletion in LysMCre-C/EBPβfl/fl microglia in
vivo and subsequent attenuated pro-inflammatory gene
expression
We were next interested to study the consequences of
microglial C/EBPβ deletion in vivo. A first step was to
estimate the efficiency of LysMCre-induced recombin-
ation of C/EBPβ LoxP sites in microglial cells in vivo. To
this end, microglia was acutely isolated by immunomag-
netic separation from the whole brain of C/EBPβfl/fl and
LysMCre-C/EBPβfl/fl adult mice treated systemically with
LPS or vehicle for 16 h. At the dose and time frame
used, systemic LPS induces a neuroinflammatory re-
sponse with increased C/EBPβ expression in the CNS
[26]. C/EBPβ protein was not detected by Western blot
in microglia protein extracts from vehicle-treated mice
of both genotypes. Systemic LPS induced the strong ex-
pression of C/EBPβ Full and LAP protein isoforms in C/
EBPβfl/fl microglia, and this induction was completely
ablated in microglia isolated from LPS-treated LysMCre-
C/EBPβfl/fl mice brains (Fig. 6a, b). These findings were
confirmed and extended by immunocytochemistry for
C/EBPβ in cytospin microglial preparations. Immuno-
staining for the microglial markers CD68 (Fig. 6c) and
Iba1 (not shown) confirmed the microglial nature of the
ex vivo isolated cells. As shown in Fig. 6c, d, C/EBPβ
immunoreactivity was not observed in microglia from
vehicle-treated mice of both genotypes, whereas it was
present in virtually 100% of microglial cells from LPS-
treated C/EBPβfl/fl mice. In these cells, C/EBPβ showed
nuclear localization. In contrast, in LPS-treated LysMCre-
C/EBPβfl/fl microglial cytospin preparations, C/EBPβ im-
munoreactivity was only observed in 11 ± 1% of microglial
cells (Fig. 6c, d). These findings demonstrate a robust C/
EBPβ deletion in LysMCre-C/EBPβfl/fl microglial cells not
only in vitro, where the efficiency of recombination
approaches 100%, but also in vivo where this efficiency
approaches 90%. These results support the use of
LysMCre-C/EBPβfl/fl mice as a model to study the func-
tional effects of microglial C/EBPβ in vitro and in vivo.
To investigate the role of C/EBPβ on gene expression
in activated microglia in vivo, we isolated microglia from
the brains of vehicle or LPS-treated (16 h) C/EBPβfl/fl
and LysMCre-C/EBPβfl/fl mice, and the expression of
selected genes was assessed by quantitative real-time
PCR (qRT-PCR). For this analysis, we included the pro-
inflammatory cytokines Tnf, Il23a and Csf3 and the key
enzymes in the production of the inflammatory mediator
prostaglandin E2 (Ptges) and the free radical superoxide
anion (Cybb). These are genes with a prominent role in
microglial activation whose expression in cultured micro-
glia was significantly dependent upon C/EBPβ according
to RNAseq data. We first confirmed that the expression of
these genes was affected by C/EBPβ by analyzing their
expression by qRT-PCR in a new series of microglial
cultures independent from those used to generate RNA-
seq data. As shown in Fig. 7 (insets), C/EBPβ deficiency
resulted in decreased LPS- and/or LPS + IFNγ-induced
expression of these genes in cultured microglia. Interest-
ingly, in vivo expression of these five genes was upregu-
lated by systemic LPS in microglia, and in all cases, these
increases were significantly blunted in microglia from
LysMCre-C/EBPβfl/fl mice (Fig. 7). These results demon-
strate for the first time that the specific absence of C/EBPβ
in microglia in vivo results in attenuated expression of
pro-inflammatory genes.
Deletion of C/EBPβ in myeloid cells is protective in an
animal model of multiple sclerosis
In order to test whether the myeloid-specific C/EBPβ ab-
sence and the resulting attenuation of microglial activation
have neuroprotective effects in vivo, we induced EAE, an
animal model of multiple sclerosis, in LysMCre-C/EBPβfl/fl
mice. We first analyzed the time course of C/EBPβ expres-
sion changes in EAE in three spinal cord and three brain
regions of wild-type mice. Figure 8a, b shows the results
obtained in the thoracic spinal cord and hindbrain. Similar
findings were obtained in the cervical and lumbar spinal
cord and in the midbrain and forebrain (data not shown).
EAE was associated with increased C/EBPβ mRNA levels
(See figure on previous page.)
Fig. 5 Ontology enrichment analyses reveal biological implication of obtained DEGs with microglial processes. C/EBPβfl/fl and LysMCre-C/EBPβfl/fl
DEGs where fed into the Genecodis platform for ontology enrichment. a p value and gene percentage annotation graph of the biological process
(BP) category from Gene Ontology database (hypergeometric distribution). b p value and gene percentage annotation graph from Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway enrichment analyses (hypergeometric distribution). c–e Heatmap of genes annotated with the
enriched categories shown above (hierarchical clustering, average linkage, Euclidean distance, scale in SD over normalized gene expression
in log2 values). Note the existence of gene clusters with distinct patterns of gene expression changes, e.g. cluster B in f corresponds to
lysosome-related genes with reduced expression upon LPS ± IFNγ treatments, in C/EBPβfl/fl microglia that is attenuated in LysMCre-C/
EBPβfl/fl microglia. In this figure, WT and KO refer to C/EBPβfl/fl and LysMCre-C/EBPβfl/fl, respectively
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in all regions analyzed. The most marked increase was ob-
served on day 14. A moderate increase on days 21 and 28
was observed in some of the CNS regions analyzed, such
as the thoracic spinal cord (Fig. 8a, b). To study whether
these mRNA changes were also observed at the protein
level, a time course analysis of C/EBPβ protein expression
was performed in thoracic spinal cord by Western blot. As
shown in Fig. 8c, d, a marked increase in C/EBPβ protein
levels was observed on day 14, in correspondence with the
mRNA data. Out of the three C/EBPβ isoforms, LAP
showed the highest expression in these samples.
We next analyzed the clinical course of EAE in
LysMCre-C/EBPβfl/fl mice and compared it with that
of the two parent lines, LysMCre and C/EBPβfl/fl. Both
parent lines showed a very similar course of the disease.
Mice started to develop multiple sclerosis-like symptoms
Fig. 6 Reduced C/EBPβ expression in LysMCre-C/EBPβfl/fl microglia in vivo. a Representative Western blot showing C/EBPβ protein levels in microglia
acutely isolated in vivo from the brains of C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice treated i.p. with vehicle (C) or LPS (4 mg/kg) for 16 h. Two C/EBPβ
isoforms are detected, Full (~38 kDa) and LAP (~35 kDa). b Quantification of Western blot signals from experiments as that shown in a (n = 4
mice/condition. C/EBPβ protein levels are normalized using β-actin levels. Data are shown as mean + SEM. LPS induces a significant increase in
C/EBPβ protein levels in C/EBPβfl/fl microglia (***p< 0.001, compared with respective vehicle) and not in LysMCre-C/EBPβfl/fl microglia (###p< .001, compared
with C/EBPβfl/fl). c Immunocytochemistry for C/EBPβ (red) and the microglial marker CD68 (green) in cytospin preparations of microglia isolated from the brains
of C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice treated as in a. Note the absence of C/EBPβ immunoreactivity in microglia from vehicle-treated mice, the nuclear
C/EBPβ staining in virtually all microglial cells from LPS-treated C/EBPβfl/fl mice and the presence of C/EBPβ in a small fraction of microglial
cells from LPS-treated LysMCre-C/EBPβfl/fl mice. Scale bar 25 μm. d Quantification of the proportion of C/EBPβ immunoreactive microglial cells
in cytospin preparations as that shown in c. Data are expressed as percentage of C/EBPβ immunoreactive microglial cells and are shown as
mean + SEM (n = 3 mice/condition). ***p < 0.001, compared with respective vehicle; ###p < .001, compared with respective C/EBPβfl/fl
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10 days after immunization. These symptoms progressed
steadily, peaked on day 20 and then plateaued until the
end of the experiment on day 52. In contrast, LysMCre-C/
EBPβfl/fl mice showed attenuated EAE symptoms with a
milder initial phase, a lower score at the peak of the dis-
ease and a partial recovery phase (Fig. 8e). Since no differ-
ences were observed between both parent lines, this
experiment was repeated twice using only C/EBPβfl/fl mice
as the control. In both experiments, LysMCre-C/EBPβfl/fl
mice showed a highly significant reduction in EAE score
with a similar profile as that of experiment 1 (data not
shown). The incidence of EAE in the three experiments
was similar for both genotypes (73% (30/41) for C/EBPβfl/
fl mice and 68% (26/38) for LysMCre-C/EBPβfl/fl mice),
and mortality was higher in C/EBPβfl/fl mice (12%; 5/41)
than in LysMCre-C/EBPβfl/fl mice (5%; 2/38).
Finally, C/EBPβ expression was studied in human mul-
tiple sclerosis. To this end, C/EBPβ protein levels were ana-
lyzed by Western blot in temporal cortex postmortem
samples from multiple sclerosis and non-neurological con-
trols. As shown in Fig. 8f, g, all three C/EBPβ isoforms were
detected, LAP being the most expressed. Interestingly, pro-
tein levels of Full and LAP, the two C/EBPβ activator iso-
forms, were increased in multiple sclerosis samples by 55%
(p < 0.05) and 93% (p < 0.001), respectively.
Discussion
C/EBPβ-deficient mice show reduced neuronal damage
induced by excitotoxic or ischemic insults in vivo [7, 9].
Since C/EBPβ is expressed by many cell types, the ques-
tion of which is the cell type(s) responsible for the neuro-
protective effects of C/EBPβ absence in these models is of
interest. In neuron–microglia co-cultures, the absence of
C/EBPβ only in microglial cells completely abrogates their
neurotoxic effects elicited by LPS + IFNγ activation [3].
This led us to hypothesize that C/EBPβ inhibition in the
microglia could have therapeutic potential as a target to
attenuate deleterious effects of neuroinflammation. As a
Fig. 7 Reduced pro-inflammatory gene expression in C/EBPβ-deficient microglia in vivo and in vitro. Expression of C/EBPβ and five pro-inflammatory
genes (Tnfa, Il23a, Csf3, Ptges and Cybb) was analyzed by qRT-PCR in microglia isolated from the brains of C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice
treated i.p. with vehicle (C) or LPS (4 mg/kg) for 16 h (n = 4 mice/condition). Insets show the expression of the same genes in primary microglial
cultures from both genotypes treated with vehicle (C), LPS (100 ng/mL) or LPS + IFNγ (1 ng/mL) for 6 h (n = 4 independent experiments). In all graphs,
data are shown as mean + SEM. The asterisk shows the significance of the treatment effect, *p < 0.05; **p < 0.01; ***p < 0.001 compared with the
respective control conditions. The number sign shows the significance of the genotype effect; #p < 0.05; ##p < 0.01; ###p < 0.001 compared with the
respective C/EBPβfl/fl condition
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proof of concept, we have generated mice with C/EBPβ
deficiency in myeloid cells. The results here presented
show a marked attenuation of clinical symptoms of EAE
in these mice. Besides, RNAseq analysis of cultured micro-
glia shows that C/EBPβ plays a key role in the regulation
of gene transcription in microglial activation and provides
possible explanations for the neuroprotective effects of C/
EBPβ absence in myeloid cells.
In order to produce C/EBPβ deletion in microglia, we
have used the Cre-LoxP approach with Cre expression
under the control of the LysM promoter [27]. Unlike
astrocytes, for which GFAP promoter is considered the
gold standard, there is not an ideal promoter to drive Cre
expression in microglia. Promoters of LysM, CD11b, F4/
80, CSF1 receptor or Iba1 genes have been used success-
fully, and in the last few years, CX3CR1 is becoming the
most widely used promoter in this respect (reviewed by
[28]), but in all cases, Cre expression is induced not only
exclusively in microglia but also in other subsets of
myeloid cells. The LysMCre mouse line has been used
extensively to induce Cre expression in myeloid cells,
particularly in macrophages and microglia. Data from
crossing LysMCre mice with reporter mice have shown
functional Cre in 30–45% of microglial cells in control
CNS [29, 30] and strong recombination in primary
microglial cultures [30–32]. Various studies have ob-
tained positive results by using LysMCre in in vivo
models that have been attributed primarily to microglia
[33–35] or to microglia and macrophages [31, 36]. Our
data clearly show an efficiency of recombination of
LysMCre close to 100 and 90% in primary microglial
cultures and in microglia in vivo in LPS-treated mice,
respectively, supporting the use of this mouse line to
drive Cre expression in microglia in these experimental
models. In our opinion, the most likely interpretation
of the neuroprotective effects of LysM-driven C/EBPβ
deletion in EAE is that the absence of C/EBPβ in
microglia results in an attenuated neuroinflammatory
response, milder neurodegeneration and less severe EAE
symptoms. However, macrophages and granulocytes show
also LysM-driven Cre expression in this mouse line [27],
and in both cell types, C/EBPβ expression has been re-
ported [37]. We cannot therefore discard that C/EBPβ
deletion in macrophages and granulocytes accounts, at
least partly, for the neuroprotective effects observed in
LysMCre-C/EBPβfl/fl mice in EAE. Unfortunately, specific
inhibition of C/EBPβ in microglia is not feasible at
present. Strategies aimed at targeting microglia, be it
nanoparticles, vectors or other approaches, cannot avoid
targeting also macrophages and often other myeloid cells
[38]. Although we would favor a microglial-specific strat-
egy, these results suggest that, if unavoidable, C/EBPβ in-
hibition not only in microglia but also in microglia-related
cells would not be necessarily undesirable.
In contrast to mice with full C/EBPβ deficiency,
LysMCre-C/EBPβfl/fl mice show normal fertility and
survival. This is important in this study because it
allowed us to obtain genetically homogenous litters of
LysMCre-C/EBPβfl/fl pups from which to prepare primary
microglial cultures in sufficient amounts to thoroughly
characterize the role of C/EBPβ in microglial activation in
vitro. In agreement with data from microglial cultures of C/
EBPβ-deficient mice [3], LysMCre-C/EBPβfl/fl microglia in
culture showed normal growth and proliferation and
reduced NOS2 expression and NO production upon LPS +
IFNγ challenge. Since NO production is an important con-
tributor to AICD in microglia [25], we hypothesized that
AICD, a mechanism of elimination of overactivated cells
best described in T cells [39], could be attenuated in
LysMCre-C/EBPβfl/fl microglia. Strong AICD was observed
in LPS + IFNγ-treated C/EBPβfl/fl microglial cells, but this
was unaffected by C/EBPβ absence indicating that C/EBPβ-
independent factors play important roles in microglial
AICD. Since AICD is a protective mechanism that prevents
overactivation [39], its maintenance in the absence of
C/EBPβ could be a positive outcome of an eventual
pharmacological strategy based on the inhibition of
microglial C/EBPβ.
The RNAseq analysis is the greatest leap forward this
study provides on the characterization of the role of C/
EBPβ in microglia. Various studies have analyzed the
role of C/EBPβ on gene expression by microarrays after
genetic deletion, inhibition by RNAi or overexpression
in a variety of cell types. Particularly relevant are the
studies that have shown important effects of C/EBPβ
on LPS + IFNγ- [40] or IFNγ- [41] induced gene
expression in macrophages. Studies in other cell types
such as anaplastic large cell lymphoma have demonstrated
(See figure on previous page.)
Fig. 8 Neuroprotective effect of microglial C/EBPβ deficiency in EAE. a–d Time course analysis of C/EBPβ expression in the CNS in EAE. Expression
was analyzed in vehicle-treated (CFA) mice and in EAE at 9, 14, 21 and 28 days post-injection (DPI). a, b C/EBPβ expression at mRNA level by
qRT-PCR in the thoracic spinal cord (a) and hindbrain (b). c Representative Western blot image of C/EBPβ protein expression in the thoracic spinal
cord in EAE. d Quantification of the C/EBPβ protein isoform LAP (n = 4–6 mice/condition). *p < 0.05; ** p < 0.01 compared with CFA. e EAE clinical
scores of mice with myeloid C/EBPβ deficiency (LysMCre-C/EBPβfl/fl mice, n = 10) and the two parental control mouse lines (LysMCre, n = 12; C/
EBPβfl/fl n = 12). Data show mean ± SEM. ***p < 0.001. f Western blot showing C/EBPβ protein levels in temporal cortex postmortem samples from
three non-neurological controls (CT) and three multiple sclerosis (MS) patients. The three C/EBPβ isoforms, Full (~38 kDa), LAP (~35 kDa) and LIP
(~21 kDa), are detected in these samples. g Quantification of C/EBPβ Western blots as that in f. Data show mean + SEM, n = 4 controls, n = 5 MS,
*p < 0.05; ***p < 0.001
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a role or C/EBPβ in the expression of immune response
genes [42]. The present study is the first to analyze the
role of C/EBPβ in microglia with a transcriptomic ap-
proach and also the first one to analyze the role of C/EBPβ
by RNAseq in any cell type. It shows massive changes in
gene expression in microglia caused by the absence of C/
EBPβ. One thousand sixty-eight genes show significant
differences in expression in C/EBPβ-deficient microglia.
Most of these genes, 867, were also affected by LPS ±
IFNγ confirming the role of C/EBPβ in microglial activa-
tion, but interestingly, C/EBPβ absence affected the ex-
pression of 201 genes that were not affected by treatment,
indicating a role for C/EBPβ also in the biology of non-
activated microglia. Gene Ontology enrichment analysis of
the 1068 genes affected by microglial C/EBPβ deficiency
identified five GO terms related to immune/inflammatory
response among the 25 most significant GO terms. This is
a strong confirmation of a key role for C/EBPβ in the
regulation of the inflammatory gene program in microglia
that others and we have proposed on the basis of the ana-
lysis of a limited number of genes [3, 7, 8, 24]. Relevant C/
EBPβ-dependent genes among these classes include toll-
like receptors and related proteins (Tlr1, Tlr7, Tlr8, Tlr9,
Cd14, Cd180, Ly86, Nod2), cytokines (Il1a, Il12a, Il23a,
Mif, Cxcl2, Cxcl3), cytokine receptors (Tnfrsf1a, Tnfrsf1b,
Ccr1, Ccrl2, Csf1r) and enzymes such as inflammation-
related kinases (Rps6ka4, Mapkapk2), prostaglandin
synthetic enzymes (Ptges, Ptgs2 (=Cox2)) or NADPH
oxidase subunits (Cybb, Ncf1). A remarkable effect of
C/EBPβ deficiency was observed in the expression of
Nlrp3, a key component of the inflammasome [43].
Altogether, these findings show that the phenotype of LPS
± IFNγ-treated microglia is markedly altered by the
absence of C/EBPβ, showing reduced responsiveness and
attenuated responses in most arms of the pro-inflammatory
program. KEGG pathway enrichment analysis also identi-
fied pathways related to inflammatory responses, such as
chemokine signaling or cytokine–cytokine receptor inter-
action, but somewhat unexpectedly, three pathways related
to phagocytosis among the five most significant KEGG
pathways. Particularly interesting is the group of lysosome-
related genes. The significant genes in this group had a re-
markably homogenous pattern of LPS ± IFNγ-induced
downregulation in C/EBPβfl/fl microglia that was blunted in
LysMCre-C/EBPβfl/fl microglia. These genes included
degradative enzymes such as proteases (Ctss, Lgmn),
nucleases (DNAse2a), sulfatases (Ids, Gns, Arsb) and
glycosylases (Naga) and genes needed for lysosome
acidification and assembly (Atp6v0a1, Atp6v0b, Ap1g2,
Ap1s1, Ap3m2). The higher expression of lysosome genes
may explain the improved ability of C/EBPβ-deficient
microglia to eliminate phagocytosed bacteria that we have
observed. This pattern of attenuated pro-inflammatory gene
expression and improved phagocytic and digesting capacity
could be of interest in a neurodegeneration context where
phagocytosis of cell debris and abnormal protein deposits is
necessary, whereas chronic production of pro-inflammatory
mediators can be detrimental.
The possibility to acutely isolate microglial cells from
the adult CNS has allowed us to estimate the efficiency
of C/EBPβ deletion in LysMCre-C/EBPβfl/fl microglia in
vivo, and the data obtained shows it to be very high,
close to 90%. This is a critical point because it opens the
possibility to use these mice to study for the first time
the functional role of C/EBPβ in microglia in vivo which
was the initial goal when generating this colony. In order
to analyze the role of C/EBPβ on transcription of microglial
genes in vivo, we selected a group of five pro-inflammatory
genes (Tnfa, Il23a, Csf3, Ptges and Cybb) that (1) are regu-
lated by C/EBPβ in microglia in culture as shown by RNA-
seq data; (2) have a well-established role in microglial
activation; and (3) play a pathogenic role in EAE. Thus,
genetic deletion of Ptges [44] and pharmacological in-
hibition of Tnfa [45] or Cybb [46] result in a significant
attenuation of clinical symptoms of EAE, whereas gen-
etic deletion of Il23a [47] or Csf3r [48] completely pre-
vent the appearance of clinical EAE. The expression of
these five genes in acutely isolated microglia was in-
duced by systemic LPS injection in accordance with
their pro-inflammatory character. Intriguingly, this ex-
pression was markedly attenuated in microglia isolated
from LysMCre-C/EBPβfl/fl mice. This demonstrates that
also in vivo C/EBPβ plays a major role in the regulation
of pro-inflammatory gene expression in microglia.
Finally, robust neuroprotection from EAE was observed
in LysMCre-C/EBPβfl/f mice in three independent experi-
ments. This neuroprotective effect is probably caused by
the absence of C/EBPβ not only in microglia but also in
monocyte-derived macrophages since both cell types are
important in EAE pathogenesis [49, 50] and LysMCre
will recombine in both [28]. The abovementioned pro-
inflammatory genes Tnfa, Il23a, Csf3, Ptges and Cybb
are candidates to mediate this effect, but given the role
of C/EBPβ as transcription factor, we favor the idea that
this effect is mediated by a higher number of genes directly
or indirectly regulated by C/EBPβ and that C/EBPβ absence
results in a global alteration of the phenotype of activated
microglia/macrophages, as demonstrated by the RNAseq
analysis in cultured microglia, rather than by an effect of
one or a few genes. These data strongly support the search
for strategies to selectively inhibit C/EBPβ in microglia or
microglia/macrophages as potential therapies in neuro-
logical disorders with a strong neuroinflammatory com-
ponent. The neuroprotection observed in LysMCre-C/
EBPβfl/fl mice in EAE together with the increased C/
EBPβ expression in human multiple sclerosis samples
point to this disease as a particularly suitable indication
for such therapies.
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Conclusion
LysMCre-C/EBPβfl/fl mice show robust C/EBPβ deletion
in myeloid cells and are a good tool for the study of the
role of C/EBPβ in these cells. In vivo and in vitro data
support an important role for C/EBPβ in the regulation
of pro-inflammatory responses in microglia. Moreover,
RNAseq results demonstrate the implication of C/EBPβ
also in other cellular programs in activated microglia
and also in non-activated microglia. Finally, C/EBPβ ab-
sence results in attenuated EAE supporting a therapeutic
potential for C/EBPβ inhibition.
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